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Tumorigenesis involves multistep genetic alterations. To elucidate the microRNA (miRNA)–gene
interaction network in carcinogenesis, we examined their genome-wide expression profiles in 96
pairs of tumor/non-tumor tissues from hepatocellular carcinoma (HCC). Comprehensive analysis of
the coordinate expression of miRNAs and mRNAs reveals that miR-122 is under-expressed in HCC
and that increased expression of miR-122 seed-matched genes leads to a loss of mitochondrial
metabolic function. Furthermore, the miR-122 secondary targets, which decrease in expression, are
good prognostic markers for HCC. Transcriptome profiling data from additional 180 HCC and 40 liver
cirrhotic patients in the same cohort were used to confirm the anti-correlation of miR-122 primary
and secondary target gene sets. The HCC findings can be recapitulated in mouse liver by silencing
miR-122 with antagomir treatment followed by gene-expression microarray analysis. In vitro miR-
122 data further provided a direct link between induction of miR-122-controlled genes and
impairment of mitochondrial metabolism. In conclusion, miR-122 regulates mitochondrial
metabolism and its loss may be detrimental to sustaining critical liver function and contribute to
morbidity and mortality of liver cancer patients.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most aggressive
human malignancies, common in Asia, Africa, and the areas
with endemic infections of hepatitis-B or -C viruses (HBV or
HCV) (But et al, 2008). It has the third highest mortality rate
among cancers worldwide and since the 1990s, the second
highest cancer mortality rate in China. Globally, the 5-year
survival rate of HCC iso5% andB600 000 HCC patients die
each year (Parkin et al, 2005; Hao et al, 2009). The high
mortality associated with this disease is mainly attributed to
the failure to diagnose HCC patients at an early stage and a lack
of effective therapies for patients with advanced stage HCC.
Although surgery remains the most effective treatment for
HCC, the majority of patients are inoperable at presentation
because of late diagnosis (Lee et al, 2007; Sun et al, 2007). The
consequent improvement in long-term survival of post-
surgery patients is only modest because of a high recurrence
rate of intrahepatic metastases that develop through invasion
of the portal vein or spread to other parts of the liver
(Poon et al, 2001). Understanding the relationships between
phenotypic and molecular changes in HCC is of paramount
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importance to develop new diagnosis and treatment of HCC
and improve the prognosis of diagnosed patients.
Although expression of many mRNAs and microRNAs
(miRNAs) has been shown to differ between tumor and non-
tumor tissue (Croce, 2008), the direct relevance of such
differential regulation is unclear. Changes in chromosomal
DNA, in expression of miRNAs, or other transcriptional/post-
transcriptional regulators may contribute to the coordinate
regulation of groups of transcripts, driving tumor progression.
Expression of additional miRNAs and mRNAs may subse-
quently change in further driving the process of carcinogenesis
or in responding to it. Driver miRNAs may be distinguished
from responder miRNAs by characteristics of miRNA targeting
(Lim et al, 2005) in coordinately regulated mRNAs (Linsley
et al, 2007). In the simplest case, miRNAs driving differential
expression should be anti-correlated with their targets, that is
over-expressed in tissues with decreased target transcript
expression and under-expressed in tissues with increased
target transcript expression.
We examined mRNA- and miRNA-expression profiles of
tumor and adjacent non-tumor liver tissue from HCC patients.
The patient population was selected from a region of endemic
HBV infection, and HBV infection appears to contribute to the
etiology of HCC in these patients. About 88% of the patients in
this study tested positive for HBV antigen; patients testing
positive for HCVantigen were excluded. In these HCC patients,
who were found to be generally under-expressing miR-122
relative to the control population and in mice treated with miR-
122 antagomir, miR-122 expression was both inversely corre-
lated with expression of genes bearing potential target sites for
miR-122 and positively correlated with expression of pathways
related to liver metabolic function. These results suggest that
miR-122 regulation of transcripts may be a driver of differences
in metabolic function between tumor and adjacent non-tumor
tissue, and within each tissue type and extend literature reports
of the association of miR-122-expression levels with lipid
metabolism (Jopling et al, 2005; Esau et al, 2006; Elme´n et al,
2008a, b; Coulouarn et al, 2009) and suppressing the metastatic
properties of HCC (Tsai et al, 2008; Coulouarn et al, 2009).
Results
Integrating miRNA- and mRNA-expression
profiling
We conducted mRNA- and miRNA-expression profiling on
tumor and adjacent non-tumor tissues from 96 HCC patients.
Among 220 miRNAs profiled, miR-122 is the most highly
expressed miRNA in tumor and in adjacent non-tumor liver
tissue (Figure 1A), agreeing well with published work (Lagos-
Quintana et al, 2002). On average, adjacent non-tumor liver
tissue contained B150000 copies of miR-122 per 10pg
(approximately one cell) of input RNA. In addition, miR-122
expression was decreased in tumor tissue relative to non-tumor
tissue with an average level almost two-fold lower than in
adjacent liver tissue (Figure 1B), ranking 14th out of 220
miRNAs for decreased expression in HCC by rank-sum
P-value, and showing the largest absolute change in expression
between HCC and adjacent non-tumor tissue, confirming earlier
observations (Kutay et al, 2006; Budhu et al, 2008).miR-122was
expressed more variably in tumors than in corresponding non-
tumor tissues (the s.d. of log10 expression level is 0.30 in tumor
versus 0.13 in non-tumor). miRNAs whose expression was
reduced comparably or even more significantly than miR-122 in
HCC include miR-139, miR-99a, miR-10a, miR-199a/miR-199a*,
miR-450, miR-378, miR-125b, miR-214, miR-422b, miR-424, miR-
451, andmiR-101. In 34 patients suffering from cirrhosis without
HCC, miR-122 was reduced approximately three-fold relative to
levels in non-tumor tissue from HCC patients, and across in all
tissues examined miR-122 was reducedB25% in the presence
versus in the absence of hepatitis-B antigen expression (data not
shown), suggesting that liver diseases other than HCC may also
decrease miR-122 expression.
To identify transcripts whose expression was associated with
expression of particular miRNAs, we scored transcripts for
correlation of their expression levels with the expression levels
of 220 humanmiRNAs in the 96 paired tumor and adjacent non-
tumor tissues. Transcripts correlated with miRNAs with
correlation coefficients 40.5 or o0.5 were identified. Over
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Figure 1 miR-122 is the most abundant miRNA in adjacent non-tumor liver tissue, and its expression is reduced on average and more variable in HCC tumors.
(A) Expression levels of 220 human miRNAs in tumor and adjacent non-tumor tissue; x axis: average expression levels in copies per 10 pg of mRNA; y axis: average of
the log10 ratios of miRNA expression in each tumor to the mean-expression level for that miRNA in adjacent non-tumor tissue. (B) Expression levels of miR-122 in paired
adjacent non-tumor (left) and tumor tissues from 96 HCC patients. Triangles represent individual subjects, whereas the box-plots show the median (horizontal bar), 25th–
75th percentile range (box), 1.5 times the interquartile range (whiskers) and outliers (plusses) of the distribution of miR-122 expression. MiR-122 was significantly
differentially expressed between tumor and adjacent non-tumor liver tissues (rank-sum P-value, 1.75e–13; miR-122 ranked 14th of 220 miRNAs).
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1000 transcripts were correlated and over 1000 transcripts were
anti-correlated with miR-122 at this level. Among the 220
miRNAs profiled, only 13 miRNAs were found correlated with
X1000 transcripts and anti-correlated withX1000 transcripts.
Identification of driver miRNA
To determine which of the miRNAs might be driving
expression of its correlated transcripts, we examined the sets
of correlated or anti-correlated genes for miRNA seed region
enrichment in their 30UTRs (Lim et al, 2005).We calculated the
hypergeometric P-value for enrichment of the seed sequences
of each miRNA in the 30UTRs of its correlated and anti-
correlated genes, and found 13 miRNAs with expectation or
E-valueo0.01 (P-value corrected for testing of 4096 hexamers)
that remained significant after further correction for examina-
tion of 241miRNA-correlated gene sets (Figure 2). As a control,
for each set of mRNAs correlated to a particular miRNA, we
also examined enrichment for seed matches to all other
miRNAs. Only miR-122 negatively correlated genes showed
more significant enrichment for seed matches to the correlated
miRNA itself than for seed matches to all other miRNAs, and
retained significance after correcting for examination of 241
gene sets. The miR-122 correlated and anti-correlated genes
are displayed in Supplementary Figure 1.
Characterization of miR-122-associated
transcripts
Transcripts anti-correlated with miR-122 are potential miR-122
targets. The transcripts most highly anti-correlated with miR-
122 expression were highly enriched for the presence of the
miR-122 central seed hexamer, CACTCC, in the 30UTR. Among
the 1106 negatively correlated transcripts, 321 of 892 annotated
transcripts contained the 30UTR hexamer CACTCC, out of 4097
total transcripts containing that hexamer. This hexamer was
ranked most highly by enrichment test with a hypergeometric
E-value of enrichment of 5e33. In general, the miR-122
negatively correlated transcripts were enriched for cell-cycle
genes (among KEGG Pathways,‘cell-cycle’ ranked most highly
with an E-value of 4e18, 35 of 199 annotated genes
overlapped with 109 ‘cell-cycle’ genes). Surprisingly, those
negatively correlated CACTCC seed-matched genes were not
significantly enriched for cell-cycle annotation (E40.01) and
did not significantly overlap with the negatively correlated
cell-cycle genes. The data suggests that miR-122 is unlikely to
directly regulate the cell cycle in these patients. Thus, the seed-
matched genes had no significant KEGG Pathway annotation.
Transcripts positively correlated with miR-122 were not
enriched for 30UTR seed matches to miR-122. Interestingly,
these 1042 transcripts were enriched for genes coding
for mitochondrially localized proteins (among GO Cellular
Components, ‘mitochondrion’ ranked most highly with an
E-value¼9e33, 117 of 562 annotated genes overlapped with
785 ‘mitochondrion’ genes) and for metabolic functions
(among KEGG Pathways, ‘fatty-acid metabolism’ ranked
most highly with an E-value¼5e16, 27 of 307 annotated
genes overlapped with 49 ‘fatty-acid metabolism’ genes;
‘valine, leucine, and isoleucine degradation’ ranked No. 2,
E-value¼9e13, 23 of 307 annotated genes overlapped with
44 ‘valine, leucine, and isoleucine degradation’ genes). The
great majority of transcripts involved in fatty-acid and amino-
acid metabolism were mitochondrially localized, with highly
significant overlap between all three pairwise comparisons
(single-test hypergeometric P-values—mitochondrion/fatty-
acid metabolism overlap: P¼7.4e12; mitochondrion/
valine–leucine–isoleucine degradation overlap: P¼6.2e22;
fatty-acid metabolism/valine–leucine–isoleucine degradation
overlap: P¼3.1e9). Thus, miR-122 expression appeared
positively associated with mitochondrially related metabolic
functions in human liver.
In vivo validation of the miR-122-regulated genes
We wanted to test whether the seed-matched genes were
directly targeted by miR-122, and further, whether the
transcripts encoding mitochondrially localized proteins were
regulated as a consequence of miR-122 expression indepen-
dent of tumor status. To test the direct and indirect effects of
loss of miR-122 alone, in vivo silencing of miR-122 was
performed by antisense inhibition of miR-122 (anti-miR-122)
in wild-type mice. Either 1 week or 4 weeks (Esau et al, 2006)
post-treatment, livers were subjected to microarray profiling
(Figure 3A). We examined the consensus of multiple animals
to minimize issues associated with animal-to-animal and
array-to-array variations in gene expression. A total of 689
up-regulated transcripts from the consensus of both time
points were enriched for 30UTRmatches to the central miR-122
seed hexamer CACTCC in both human and mouse miR-122
(30UTR hexamer ‘CACTCC’ ranked most highly by enrichment
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Figure 2 miR-122 is the miRNA most strongly associated with seed-matched
genes in tumor and adjacent non-tissues. Transcripts whose expression levels
were correlated or anti-correlated with expression levels of miRNAs were tested
for enrichment of 30UTR hexamers (seed sequences) by the hypergeometric
P-value. Shown are the E-values (Bonferroni-corrected P-values adjusted for
testing of 4096 hexamers) for enrichment of the three hexamers matching bases
1–8 of the correlated miRNA (blue dots) or bases 1–8 of other known miRNAs
(gray dots). Each column shows log10 E-values for a set of transcripts
significantly positively or negatively correlated with a particular miRNA. The
direction of correlation is indicated by ‘þ ’ for positive and ‘’ for negative or anti-
correlation. Only those transcript sets are shown for which the correlated miRNA
has an E-value of o0.01, after further adjustment for the 241 transcript sets
examined, for at least one of its 30UTR seed hexamers in a correlated or anti-
correlated transcript set. The red dashed line marks Eo0.01 after adjustment for
both 4096 hexamers tested per transcript set and for the 241 transcript sets
examined.
miR-122 regulates cancer metabolism in liver
J Burchard et al
& 2010 EMBO and Macmillan Publishers Limited Molecular Systems Biology 2010 3
test, with an E-value¼5e83, 350 of 639 annotated genes
overlapped with 3904 CACTCC hexamer-containing genes).
As with the genes negatively correlated with miR-122 in HCC
patients, no significant biological annotation was associated
with the seed-matched genes up-regulated by anti-miR-122 in
mouse livers. The most significant biological annotation for
1865 consensus down-regulated genes was mitochondrial
localization (among GO Cellular Components, ‘mitochondrion’
ranked most highly, E-value¼2.5e72, 219 of 1180 annotated
genes overlapped with 663 ‘mitochondrion’ genes). Enrich-
ment for mitochondrially localized gene products was not
observed in genes down-regulated in treatments by antago-
nists to other miRNAs (data not shown). The mitochondrial
genes down-regulated by anti-miR-122 treatment were en-
riched for metabolic functions (among KEGG Pathways,
‘oxidative phosphorylation’ ranked most highly, E-value¼
5e20, 53 of 540 annotated genes overlapped with 116
‘oxidative phosphorylation’ genes; ‘valine, leucine, and
isoleucine degradation’ ranked No. 2, E-value¼6e8, 21 of
540 annotated genes overlapped with 43 genes in this set;
‘fatty-acidmetabolism’ rankedNo. 3, E-value¼2e5, 18 of 540
annotated genes overlapped with 43 genes in this set). These
results confirm our observations in human HCC samples and
show that loss of miR-122 alone can up-regulate seed-matched
genes and down-regulate mitochondrially localized genes that
are critical for metabolic functions.
Characterization of miR-122-regulated
orthologous genes
To the extent that miR-122 targeting is conserved from mouse
to human, we can expect mouse genes up-regulated by anti-
miR-122 to be orthologous to human genes anti-correlated
with miR-122 in HCC. Further, if biological pathways regulated
by miR-122 are conserved as well, mouse orthologs of genes
positively correlated with miR-122 should be down-regulated
by anti-miR-122. To this end, we compared the mouse
signature genes with human genes anti-correlated and
correlated with miR-122. Restricting the analysis to orthologs
represented on the human and the mouse microarrays among
both putative direct targets and putative downstream targets,
human and mouse genes showed significant overlap for
regulations in the same direction (overlap of human genes
anti-correlated with miR-122 and mouse genes up-regulated
by anti-miR-122; hypergeometric P-value¼2.1e4; overlap
of human genes correlated with miR-122 and mouse
genes down-regulated by anti-miR-122; hypergeometric
P-value¼1.6e29), without significant overlap for regulations
in the opposite direction (hypergeometric single-test P-
value40.5). The overlap between genes negatively correlated
with miR-122 in HCC and up-regulated in anti-miR-122-treated
mice defines a set of putative miR-122 primary targets
(Supplementary Table Ia). The overlap between genes
positively correlated withmiR-122 in HCC and down-regulated
in anti-miR-122-treated mice defines putative secondary miR-
122 targets (Supplementary Table Ib).
To further show that orthologous genes are regulated by
miR-122 in the same directions in both systems, we compared
their average expression levels and their relationships with
miR-122 (Figure 3B). All significantly regulated transcripts on
the mouse microarray that can be mapped to human orthologs
were binned by the correlation of the human orthologs to miR-
122 in HCC patient tissue and the average expression ratio
(HCC versus non-tumor in human, antagomir treated versus
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Figure 3 (A) Seed-matched genes are up-regulated and mitochondrial genes
are down-regulated after inhibition of miR-122. Shown are the liver-expression
profiles of mice treated twice weekly with anti-miR-122 for 4 weeks (top four
profiles) or 1 week (bottom four profiles). Transcripts regulated in at least
one experiment with P-value of regulation o0.05 are shown. Boxes identify
consensus up-regulated and consensus down-regulated transcripts. Consensus
up-regulated transcripts were enriched for 30UTR matches to CACTCC, the
central miR-122 seed hexamer. Consensus down-regulated genes were
enriched for mitochondrially localized gene products. (B) Correlation to miR-
122 in human HCC predicts ortholog regulation by anti-miR-122 in mouse livers.
Shown is the relationship between transcript correlation with miR-122 levels in
HCC and adjacent liver tissue and changes in expression in HCC tumor and
adjacent non-tumor tissues, and in anti-miR-122-treated mice. Human/mouse
ortholog pairs are binned by the correlation coefficient of the human ortholog with
miR-122, at a rate ofB1000 human orthologs per bin. The ortholog pairs within
each bin are then restricted to those whose mouse ortholog is regulated with
Po0.05 by anti-miR-122. For each bin, the mean correlation coefficient of the
human ortholog is plotted against the mean-expression ratios in both human and
mouse contexts. Left axis/blue dots: the log10 ratio of mean tumor expression to
mean adjacent tissue expression is shown for the human orthologs in each bin.
Right axis/red dots: the mean log10 expression ratio of regulation by anti-miR-
122 is shown for the mouse orthologs in each bin. Purple box: putative primary
miR-122 targets; blue box: putative secondary miR-122 targets. Source data is
available for this figure at www.nature.com/msb.
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control in mouse liver) for orthologs in each bin was
computed. As expected for the human transcripts, the anti-
correlated genes were more highly expressed in tumor relative
to non-tumor, whereas the correlated genes were more under-
expressed. Similar dependence was observed in mouse liver
treated by the anti-miR-122, even though the binning was
based on correlation in HCC.
miR-122 regulation of mitochondrial metabolic
gene network
The mechanism of repression of mitochondrially localized
genes by decreasing miR-122 is not obvious. We reasoned that
a direct link between the degree of induction of seed-matched
genes and the magnitude of repression of mitochondrial genes
through loss of miR-122 could be observed in a group of mice,
as time, dose, and individual animal characteristics caused a
range of responses. In fact, the mean regulations of seed-
matched and mitochondrial gene sets are well correlated
across the varied responses in the treated mice (Figure 4A),
supporting a direct link between induction of miR-122 targets
and repression of mitochondrial function.
To test whether the regulation of seed-matched genes and
mitochondrial genes in human liver was directly related across
the range of patient conditions, we performed a similar
analysis on a separate transcriptome profiling dataset from
180 HCC, 40 cirrhotic, and 6 normal liver tissue samples. For
this test, we selected genes negatively correlatedwithmiR-122,
seed matched in both mouse and human 30UTRs, and
mitochondrially localized genes positively associated with
miR-122 in both mouse and human samples. Expression levels
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of these gene sets were strongly anti-correlatedwith each other
in individual HCC tumors, adjacent non-tumor tissue, and in
cirrhotic livers (Figure 4B). These data suggest that the
relationship observed in mouse is functionally conserved in
human beings. To validate the direct correlation between miR-
122 and some of the primary and secondary targets, we
determined expression of two putative direct targets,
SMARCD1 and MAP3K3 (MEKK3), a target described in the
literature, CAT-1 (SLC7A1), and three putative secondary
targets, PPARGC1A (PGC-1a), succinate dehydrogenase (SDH)
subunits A and B, after transfection of miR-122 mimetic into
PLC/PRF/5 HCC cells. The expressions of the seed-matched
genes, SMARCD1, MAP3K3, and CAT-1 were reduced upon
increased expression of miR-122, and the putative secondary
target genes, PPARGC1A, SDHA, and SDHB, showed increased
expression (Figure 4C). In contrast, the transfection of anti-
miR-122 resulted in an increased expression of seed-matched
genes and reduced expression of mitochondrial genes (Sup-
plementary Figure 2).
Function of miR-122 in mitochondrial energy
metabolism
We used functional classification of genes by total ancestry
(Yu et al, 2007) to investigate whether common functions
might link expression of miR-122 targets with mitochondrial
function. We first defined a set of putative miR-122 targets:
genes negatively correlated with miR-122 expression in HCC
tumor and adjacent tissuewith correlation coefficientso0.4,
having mouse orthologs up-regulated by anti-miR-122 with
mean log10 expression ratios 40.09 and geometric mean
P-values of up-regulationo0.05, as calculated by amicroarray
error model (Weng et al, 2006) over multiple animal
treatments. Next, we defined a set of putative miR-122
secondary targets, applying the opposite criteria to select
genes positively correlated with miR-122 in human tissue and
down-regulated by anti-miR-122 in mouse. We then identified
all miR-122 secondary targets connected to miR-122 targets
by functional similarity (Figure 5A). The most connected
secondary target, with 27 functional similarities, was PPARG-
C1A (PGC-1a). Functional similarity was frequently associated
with more direct connections. For example, among the
putative primary targets connected to PPARGC1A, MED1
(TRAP220) (Wallberg et al, 2003), and SMARCD1 (BAF60a)
(Li et al, 2008) are fellow transcriptional co-activators; and
LCMT1 (PPM1) (Leulliot et al, 2004), PPP1CC, ATF4 (CREB2),
MAP3K3 (MEKK3), and MAPKAP2 (MK2) (Wu et al, 2001)
may be involved in regulation of PPARGC1A expression.
As mentioned previously, transfection of miR-122 mimetic
could increase PPARGC1A expression. To further validate the
link of miR-122 and PGC-1a protein, we transfected PLC/PRF/5
with miR-122-expression vector, and the increase of PGC-1a
protein levels was observed (Figure 5B). Importantly, transfec-
tion of both miR-122 mimetic and miR-122-expression vector
led to a significant reduction of lactate content in PLC/PRF/5
cells (Figure 5C), whereas the anti-miR-122 treatment led to
an increase of lactate production in the PLC/PRF/5 cells
(Supplementary Figure 3). Together, the data support the
function of miR-122 in mitochondrial metabolic functions.
miR-122-regulated pathways contribute to patient
survival
As anti-miR-122-treated animals tolerate the loss of miR-122
well (Jopling et al, 2005; Kru¨tzfeldt et al, 2005; Budhu et al,
2008; Elme´n et al, 2008a, b), the question remained as to the
relevance of loss of miR-122 function to morbidity and
mortality for HCC patients. Indeed, miR-122-expression levels
on their own were not significantly related to patient survival
at the Po0.05 level (log-rank P-value¼0.09 in tumor tissue
and 0.17 in adjacent non-tumor tissue). However, when
comparing between surviving and deceased patients, the
miR-122 secondary targets were expressed at significantly
higher levels in both tumor (ANOVA P-value¼0.02) and
adjacent non-tumor (ANOVA P-value¼0.006) tissues among
the survivors. Patients in the bottom 50% for expression of the
miR-122 secondary targets in either tumor or adjacent non-
tumor tissue showed significantly shorter survival times
(Figure 6). As there is no correlation between tumor and
adjacent non-tumor samples from the same patient of miR-122
levels (r¼0.02) or of miR-122 secondary target levels
(r¼0.06), prognostic significance of each tissue appears
independent.
Discussion
Normal liver function includes building biomolecules for
export to consumer tissues of the body (Yokoyama et al, 2005).
This catabolism requires energy and liver tissue is rich in
mitochondria. Loss of mitochondrial function may in turn be
associated with loss of liver function. Dysregulation of normal
mitochondrial functions may also contribute to cancer
metabolism and hepatocarcinogenesis, as the connection
between mitochondrial dysfunction and cancer is well known
(Brandon et al, 2006). It is possible that loss of miR-122
expression in HCC may contribute to loss of liver function, a
contributor to morbidity and mortality in HBV-associated
HCC. We have shown that loss of expression of miR-122
positively correlated genes predicts poor survival for HCC
patients. In our patient cohort, expression levels of miR-122-
regulated pathways in both tumor and adjacent non-tumor
tissue appear to be independently functioning as goodmarkers
of patient prognosis.
Although miR-122 negatively correlated genes were en-
riched for cell-cycle function in HCC (E-value¼8e18), the
miR-122 seed-matched transcripts showed only random over-
lap with cell-cycle transcripts (single-test hypergeometric
P-value¼0.78). These observations suggest that there is likely
no direct connection between up-regulation of potential miR-
122 targets and up-regulation of the proliferative apparatus in
tumor tissue. Further, we did not find strong prognostic power
for patient survival in miR-122-expression levels, although a
smaller study has (Coulouarn et al, 2009). We also did not find
strong prognostic power in expression levels of proposed
miR-122 direct targets, whereas expression of the putative
secondary targets, transcripts positively correlated with miR-
122, is predictive of patient survival. Two possible implications
of these observations are that the downstream target pathways
are more connected to clinical outcome than the primary
targeting mechanisms and that downstream pathways may
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Figure 5 (A) Target-focused human/mouse network of miR-122-associated genes. Genes in this network were either putative miR-122 primary targets up-regulated by anti-
miR-122 in mouse livers and negatively correlated with miR-122 expression in human HCC, or putative miR-122 secondary targets down-regulated by anti-miR-122 in mouse
livers and positively correlated with miR-122 in human HCC. Functional similarity (Yu et al, 2007) connections are shown between putative primary and secondary targets.
Thicker blue lines emphasize the connections to PPARGC1A, the putative secondary target with the most connections to primary targets. Color of gene ovals indicates
direction of correlation with miR-122 in HKU patient samples (magenta, negative correlation; cyan, positive correlation). (B) Over-expression of miR-122 in HCC enhances
PGC-1a protein expression. PLC/PRF/5 cells were either mock transfected, transfected with vector alone, or transfected with vector expressing miR-122. Top panel: western
blot of PGC-1a protein expression in the transfected cells. Bottom panel: expression levels of miR-122 in the transfected cells, as measured by qPCR. (C) Altered miR-122-
expression level affects lactate accumulation in PLC/PRF/5 cells. Transfection of miR-122 mimetic or miR-122-expression vector caused a decrease in lactate content in PLC/
PRF/5 HCC cells. Data shown are the representative set of two independent experiments and are mean±s.d. Source data is available for this figure at www.nature.com/msb.
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form a more sensitive measure of miRNA activity than direct
measurements of miRNA-expression levels (Davis et al, 2009).
Genes that were up- and down-regulated in HCC and in anti-
miR-122-treated mice (putative primary and secondary miR-
122 targets), appear to function as a biological network.
A number of these genes are connected by functional similarity
as determined by the total ancestry method of functional
classification analysis (Yu et al, 2007). In addition, a number
of proposed primary and secondary target genes found in
this work have been previously reported to be associated
in various functional networks. The networks associated
with statin (an HMG-CoA reductase inhibitor to lower
cholesterol levels) treatment, high-fat feeding or fasting,
expression of the obesity causal gene Zfp90, and with cohesive
gene expression in normal liver overlap significantly with miR-
122 primary and secondary targets (Schadt et al, 2005, 2008;
Chen et al, 2008).
PPARGC1A is the miR-122 secondary target most connected
by functional similarity to genes up-regulated by loss of miR-
122 in both human HCC and anti-miR-122-treated mice.
PPARGC1A transcription is activated by cAMP-response
element-binding proteins (CREB) (Wu et al, 2001). Among
those genes connected to PPARGC1A in this study, PPP1CC
negatively regulates CREB, and LCMT1 (Leulliot et al, 2004)
activates PPP2A, which inhibits CaM-kinase activation of
CREB and MEK/ERK signaling in the MAP-kinase pathway
(Wu et al, 2001). The MAP-kinase pathway represented by
MAP3K3 and MAPKAP2 among genes up-regulated by loss of
miR-122 leads to phosphorylation of PPARGC1A that both
activates the protein and enhances SCF/Cdc4-mediated
degradation of the protein (Olson et al, 2008). These published
observations suggest that multiple miR-122 targets may
contribute to the down-regulation of PPARGC1A observed
with loss of miR-122.
PPARGC1A is proposed to be the master regulator of
mitochondrial biogenesis (Ventura-Clapier et al, 2008), sug-
gesting that loss of PPARGC1A expression may contribute to
the loss of mitochondrial gene expression correlated with loss
of miR-122 expression. PPARGC1A-over-expressing mouse
strains show uncontrolled mitochondrial biogenesis (Lehman
et al, 2000), whereas PPARGC1A-knockout mouse strains
showdecreased expression ofmitochondrial geneswith strain-
dependent compensatory phenotypes (Benton et al, 2008).
PPARGC1A and HNF-4 are thought to act together to stimulate
cholesterol biosynthesis (Rodgers and Puigserver, 2007), so
loss of PPARGC1A may contribute to the reduction in plasma
cholesterol seen in anti-miR-122-treated animals (Jopling et al,
2005; Esau et al, 2006; Elme´n et al, 2008a, b). SMARCD1
(BAF60a), which stimulates fatty-acid oxidation in conjunc-
tion with PPARGC1Awithout changing its expression level (Li
et al, 2008), is proposed to be a primary target of miR-122 in
this study and in a recent publication (Gatfield et al, 2009),
suggesting that increased fatty-acid oxidation seen with miR-
122 depletion (Esau et al, 2006; Gatfield et al, 2009) may be a
direct effect. Another study found that reduction of miR-122
levels in non-alcoholic steatosis was associated with increased
expression of lipogenic genes (Cheung et al, 2008). In anti-
miR-122-treated mice in this study, expression levels for genes
encoding cholesterol biosynthesis and lipid metabolism are
not tightly anti-correlated with expression levels of miR-122
seed-matched genes (data not shown), suggesting that the
observed effects of anti-miR-122 on cholesterol and lipid
synthesis may be further downstream of miR-122. Microarray
studies of anti-miR-122 in high-fat-fed mice may be of interest
in elucidating the connection betweenmiR-122 and cholesterol
biosynthesis.
Interestingly, down-regulation of SDH subunits A and B is
associated with loss of miR-122 in both mouse and human
tissues in this study. Increased expressions of both the genes
were detected in cell culture after treatment with miR-122
mimetic. Loss-of-function mutations in genes encoding sub-
units B, C, or D of SDH lead to loss of mitochondrial function
and to hereditary paraganglioma or in the case of SDHB, also to
phaeochromocytoma or renal cell carcinoma (King et al,
2006). A decline in SDH function concomitant with the loss of
miR-122 may thus increase the risk of oncogenesis.
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Recently, miR-122 has been suggested to act as a tumor
suppressor in HCC (Tsai et al, 2008; Coulouarn et al, 2009). In
the study of Tsai et al, a combination of bioinformatics and
tumor profiling was used to identify 45 genes as potential miR-
122 targets. About half of the proposed targets were anti-
correlated with miR-122 in the tumor and non-tumor tissues
profiled in our study. A total of 11 of the genes were also up-
regulated in the anti-miR-122-treated mouse livers we profiled,
suggesting cross-species conservation of the regulations these
authors identified. However, ADAM17, followed up in more
depth by Tsai et al, was not significantly anti-correlated with
miR-122 in our profiles. The study of Coulouarn et al found
gene-expression clusters associated with high and lowmiR-122
levels in 32 HCC tissue samples. Genes whose increased
expression was associated with lower miR-122 levels in these
samples included predicted miR-122 targets and genes up-
regulated in anti-miR-122-treated mice, whereas genes whose
increased expression was associated with higher miR-122
levels were enriched for lipid metabolism functions and were
more likely to be well expressed in control mice. This study
emphasized the function of HNF1A and HNF3, transcription
factors mediating hepatocyte differentiation and liver func-
tions, in potential regulation of miR-122 expression. Our study
is unable to support a primary or secondary function for these
genes. HNF3 components were uncorrelated with miR-122 in
tumor and non-tumor tissues profiled in our study andwere not
consistently regulated in anti-miR-122-treated mouse livers.
HNF1A showed no significant relationship tomiR-122 in tumor
and non-tumor profiles; we have no data onmouse expression.
Taken together, our results imply that normal mitochondrial
function in liver, including expression of mitochondrion-
associated metabolic pathways, may be maintained in part
by miR-122 expression. Impaired mitochondrial functions are
observed in many tumor types, suggesting an alternate
possibility that the observed decline in mitochondrial function
in HCC may be tumor related rather than miRNA related
(Jopling et al, 2005). Our observations that mitochondrial
function pathways and miR-122 levels also decline coordi-
nately in cirrhotic liver and in anti-miR-122-treated mouse
livers argue against this explanation.
Other connections between loss of miR-122 expression and
changes in liver function have been proposed. CAT-1 (SLC7A1)
was shown to be a direct target of miR-122 (Chang et al, 2004;
Jopling et al, 2006), and although it is negatively correlated
with miR-122 levels in HCC in this study, it is unregulated in
anti-miR-122-treated mouse livers profiled herein. Bcl-w,
recently found to be targeted by miR-122 (Lin et al, 2008),
was negatively correlated with miR-122 levels in HCC in this
study and is up-regulated in anti-miR-122-treated mouse
livers, supporting a pro-apoptotic function for miR-122 in
HCC and indicating a survival advantage to its down-
regulation in HCC. Expression of miR-122 precursors is known
to be circadian; in a recent study, eight genes were identified as
showing circadian accumulation in microarray experiments,
showing up-regulation in mouse livers treated with anti-miR-
122 and having 30UTRs down-regulated by miR-122 mimetics
(Gatfield et al, 2009). In total, 11 other genes were identified as
showing up-regulation by anti-miR-122 and having 30UTRs
down-regulated by miR-122 mimetics, but without circadian
accumulation. In this study, 13 of these 19 genes were
up-regulated by anti-miR-122 treatment in mice, including 7
of the 8 genes showing circadian accumulation. However,
only one gene, SMARCD1 (BAF60a), also showed expression
negatively correlated with miR-122 expression in our HCC
samples, emphasizing the importance of cross-species analy-
sis. Cyclin G1, found by others (Gramantieri et al, 2007) to be
anti-correlated with miR-122 in HCC, was not significantly
correlated or anti-correlated with miR-122 in our samples.
Similarly, although N-myc has been suggested as a target of
miR-122 (Girard et al, 2008), its expression levels are not
significantly correlated or anti-correlated to miR-122 levels in
this study.
Other published studies indicate thatmiR-122 is a host factor
for HCVreplication (Jopling et al, 2005, 2006; Shan et al, 2007;
Chang et al, 2008; Henke et al, 2008; Lupberger et al, 2008) and
show that HCV-infected HCC patients usually do not show a
reduction in and may in fact show an increase in miR-122
expression (Varnholt et al, 2008), although higher miR-122
levels have also been shown to predict better response of HCV
patients to standard therapy (Sheikh et al, 2008). HCVappears
to target mitochondria directly causing liver dysfunction
(Sarasin-Filipowicz et al, 2009) by a route not dependent on
decreasing miR-122 expression.
The primary targets of an miRNA may be distributed over a
variety of functional categories while resulting in a coordi-
nated secondary response, potentially through synergistic
action (Linsley et al, 2007). In our study, we found increased
lactate production in tissue culture cells after treatment with
anti-miR-122. Reduced mitochondrial oxidative phosphoryla-
tion is commonly observed in cancer cells, and we postulate
that the reduced expression of miR-122 may contribute to this
effect in HCC. In light of the observed connection between
miR-122 expression and mitochondrial function pathways in
liver, we speculate that increasing miR-122 expression may
possibly improve mitochondrial function in liver and perhaps
in liver tumor tissues. Therefore, it is of great interest to
determine the phenotypic changes of HCC after miR-122
targeting delivery in our established HCC mouse models
(Zender et al, 2008; Liu et al, 2009).
Our findings reveal potential new biological functions of
miR-122 in liver physiology. We have observed the decrease of
miR-122, a liver-specific miRNA, in HBV-associated HCC, and
loss of miR-122 appears to correlate with the decrease of
mitochondrion-related metabolic pathway gene expression in
HCC and in non-tumor liver tissues, a result that is consistent
with the outcome of treatment of mice with anti-miR-122
and is of prognostic significance for HCC patients. Further
investigation will be conducted to dissect the regulatory
function of miR-122 on mitochondrial metabolism in HCC.
Materials and methods
Tissue samples
For human HCC patient samples, resected tumor and adjacent non-
tumor liver tissues were collected from patients who had undergone
hepatectomy for curative treatment of HCC at Queen Mary Hospital,
Pokfulam, Hong Kong between 1990 and 2007. Informed consents
were obtained from patients regarding the use of the liver specimens
for research. Demographic and clinicopathologic features are sum-
marized in Supplementary Table II and elsewhere (Yi et al, 2008;
Hao et al, 2009; Lee et al, 2009; Xu et al, 2009).
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Animal care and treatments
All animal experiments were conducted according to the Institutional
American Association for the Accreditation of Laboratory Animal Care
Guidelines. Male C57BL/6 mice were obtained from The Jackson
Laboratory and were housed four to five animals per cage with a
12-h light/dark cycle. Oligonucleotides were dissolved in saline and
administered to mice based on body weight by intraperitoneal
injection. In one treatment regimen, animals were given four doses
of 100mg ASO/kg body weight, administered every other day, and
killed 1 day after the last dose. Animals treated for 4 weeks were
treated twice weekly with 50mg ASO/kg body weight, and killed 2
days after the last dose. Mice were killed in the morning, and liver was
removed for further analysis. There were no statistically significant
elevations in plasma transaminase levels after either treatment
regimen and no significant histological findings.
Reagents
Nucleic-acid reagents used in this study were as follows. The miR-122
mimetic consisted of a 50-UGGAGUGUGACAAUGGUGUUUG-30 guide
strand annealed to a [iB]AACACCAUUGUCACACUCGAAU[iB] passen-
ger strand, where iB represents an inverted abasic cap. The Let-7
mimetic consisted of a 50-UGAGGUAGUAGGUUGUAUAGUU-30guide
strand annealed to a [iB]CUAUACAACCUACUACCUGAAU[iB] passen-
ger strand. For in vitro experiments, the anti-miR-122 antagomir
consisted of a single strand, 50-dCs;dCs;lnaAs;dTs;dTs;lnaGs;dTs;
dCs;lnaAs;dCs;dAs;lna-5methylCs;dTs;dCs;lna-5methylCs;dAs-30. The
control antagomir consisted of a single strand, 50-lna-5methylCs;
dCs;lnaAs;dTs;dTs;lna-5methylCs;lnaTs;dCs;dAs;lna-5methylCs;dAs;
lna-5methylCs;dTs;lnaGs;lna-5methylCs-30. For in vivo experiments,
antagomirs were 20-O-methoxyethyl (20-MOE) phosphorothioate
modified. The anti-miR-122 antagomir consisted of a single strand,
50-ACAAACACCATTGTCACACTCCA-30. The control antagomir con-
sisted of a single strand, 50-CCTTCCCTGAAGGTTCCTCCTT-30.
RNA analysis
Total RNAwas purified from mouse in vivo samples using an RNeasy
kit (Qiagen, Valencia, CA). RNA from anti-miR-122-treated mice was
compared with RNA from mice injected with phosphate-buffered
saline. Three to five mice were analyzed for each treatment or control
group. Microarray hybridizations were performed as described
(Jackson et al, 2003). Isolation of RNA from human samples was
achieved using the following procedures. The milled tissue samples
were homogenized in cryopreservation tubes with a vortex mixer after
addition of 750–1000 ml of TRIzol reagent. Chloroform was added to
the TRIzol/GITC lysate (1:5) to facilitate separation of the organic and
aqueous components using the phaselock (Eppendorf) system. The
aqueous supernatant was further purified using the Promega SV-96
total RNA kit, incorporating a DNase treatment during the procedure.
Isolated total RNA samples were then assayed for quality (Agilent
Bioanalyzer) and yield (Ribogreen) metrics. Hybridization, labeling,
and scanning of microarrays were completed following the manufac-
turer’s recommendations (Affymetrix). Human samples were profiled
on a custom Affymetrix array, RM-HU01Aa520485 RSTA Custom
Affymetrix 1.0. Mouse samples were profiled on a custom Agilent
array, RSTA Mouse 3.0 A1. The miRNA profiling was performed by
custom quantitative PCR assays as described (Raymond et al, 2005).
Microarray data transformation and analysis was performed as
described (Irizarry et al, 2003; Jackson et al, 2003; Eklund et al,
2006). Upon publication of this manuscript, microarray data will be
available in GEO (http://www.ncbi.nlm.nih.gov/geo/info/linking.
html), under accession number GSE22058 (released on 4 June 2010).
Analysis methods
Regulated transcripts were identified in microarray gene-expression
signatures using a P-value cut-off (Po0.01 or Po0.05, as specified).
No cuts were placed on fold change in expression unless specified.
Data were analyzed using Rosetta Resolvert and MATLABt software.
Regulated transcripts were tested for enrichment of transcripts
belonging to gene sets in the GO Cellular Component (Ashburner
et al, 2000) and KEGG Pathways (Kanehisa et al, 2008) annotation
sources or of transcripts containing one or more copies of a hexamer
sequence in the 30UTR relative to a background set (i.e. the set of genes
represented on the microarray) using the hypergeometric distribution.
The P-value for enrichment of each gene set in an annotation source
or of each of 4096 possible hexamers was subjected to Bonferroni’s
correction.
Tissue culture
PLC/PRF/5 and MHCC-97L cells were transfected with 10 nM of either
let-7 or miR-122 mimetic, and cell lysates were collected 48 h post-
transfection using TRIzol (Invitrogen, Carlsbad, CA). For the miR-122-
knockdown assay, PLC/PRF/5 cells were transfected with 80mM of
either miR-122 antisense or control miR-122 antisense, and cell lysates
were collected 48h post-transfection using TRIzol (Invitrogen). Real-
time qPCR assays were performed to evaluate the expression levels of
CAT-1, SMARCD1, MAP3K3, PPARGC1A, SHDA, and SDHB using
Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City,
CA). For detection of miR-122 expression, TaqMan MicroRNA Assay
specific for miR-122 (Applied Biosystems) was used, and procedures
were in accordance with manufacturer’s protocol. The numbers of
miR-122 copies in samples were quantified with a standard curve.
The miR-122-expression vector was generated by cloning of the
genomic region containingmaturemiR-122 sequence and its 50- and 30-
flanking sequence into pcDNA3.1 vector (Invitrogen). PLC/PRF/5
cells were transfected with 2mg per well of purified miR-122 plasmids
in six-well plates using Lipofectamine 2000 (Invitrogen) as previously
described (Liu et al, 2010). For western blot analysis, cell lysates
were prepared in RIPA buffer 48 h post-transfection and probed with a
rabbit monoclonal antibody (clone 3G6) against PGC-1a (1:1000
dilution; Cell Signaling Inc., Beverly, MA), and the blot was developed
using chemiluminescent detection substrate solution (Millipore,
Billerica, MA).
Lactate assay
Cellular lactate level of PLC/PRF/5 cells after miR-122 antagomir
treatment or ectopic expression of miR-122 was determined using a
commercial lactate assay kit (BioVision, Mountain View, CA) as
described by Christofk et al (2008). All procedures were in accordance
with the manufacturer’s instruction.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (http://www.nature.com/msb).
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